• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage your publications. Semantic Scholar automatically creates author pages based on data aggregated from public sources and our publisher partners.
  • Khandaker Al Zaid Siddiquee, Shumin M. Zhang, +9 authors James Kennedy Turkson
  • Biology, Medicine
  • Proceedings of the National Academy of Sciences
  • 2007 (First Publication: 1 May 2007)
  • S3I-201 (NSC 74859) is a chemical probe inhibitor of Stat3 activity, which was identified from the National Cancer Institute chemical libraries by using structure-based virtual screening with aContinue Reading
  • Michelle A. Blaskovich, Jiazhi Sun, Alan M. Cantor, James Kennedy Turkson, Richard Jove, Saïd M. Sebti
  • Biology, Medicine
  • Cancer research
  • 2003 (First Publication: 15 March 2003)
  • Constitutively activated, tyrosine-phosphorylated signal transducer and activator of transcription (STAT) 3 plays a pivotal role in human tumor malignancy. To discover disrupters of aberrant STAT3Continue Reading
  • Lin Yang, Han C. Dan, +9 authors Jin Quan Cheng
  • Medicine, Biology
  • Cancer Research
  • 2004 (First Publication: 1 July 2004)
  • Accumulated studies have shown that activation of the Akt pathway plays a pivotal role in malignant transformation and chemoresistance by inducing cell survival, growth, migration, and angiogenesis.Continue Reading
  • Edwina C. Lerner, Yimin Qian, +7 authors Saïd M. Sebti
  • Biology, Medicine
  • The Journal of Biological Chemistry
  • 1995 (First Publication: 10 November 1995)
  • Ras-induced malignant transformation requires Ras farnesylation, a lipid posttranslational modification catalyzed by farnesyltransferase (FTase). Inhibitors of this enzyme have been shown to blockContinue Reading
  • Kaiyu Jiang, Domenico Coppola, +4 authors Jin Quan Cheng
  • Medicine, Biology
  • Molecular and Cellular Biology
  • 2000 (First Publication: 1 January 2000)
  • ABSTRACT Farnesyltransferase inhibitors (FTIs) represent a novel class of anticancer drugs that exhibit a remarkable ability to inhibit malignant transformation without toxicity to normal cells.Continue Reading
  • Jiazhi Sun, Michelle A. Blaskovich, +5 authors Saïd M. Sebti
  • Medicine
  • Cancer research
  • 1999 (First Publication: 1 October 1999)
  • Ras malignant transformation requires posttranslational modification by farnesyltransferase (FTase). Here we report on the design and antitumor activity, in monotherapy as well as in combinationContinue Reading
  • Edwina C. Lerner, Tingting Zhang, D. Benjamin Knowles, Yimin Qian, Andrew D. Hamilton, Saïd M. Sebti
  • Biology, Medicine
  • Oncogene
  • 1997 (First Publication: 18 December 1997)
  • The farnesyltransferase (FTase) inhibitor FTI-277 is highly effective at blocking oncogenic H-Ras but not K-Ras4B processing and signaling. While inhibition of processing and signaling of oncogenicContinue Reading